Neurodegenerative Disease Treatment Market to Expand at a Healthy CAGR By 2027 With Global Industry Size, Growth, Emerging Trend, Share, Opportunities, Business Overview, Competitive Landscape and Regional Forecast
SEATTLE, April 02, 2021, (PHARMIWEB) — Neurodegenerative diseases is involves progressive loss of function and structure of neurons, which sometimes also includes death of neurons. It includes a range of conditions typically affecting neurons in human brain. It primarily causes due to toxic protein substance in the brain, which it hinders the function of mitochondria in the brain. Some of the neurodegenerative diseases are caused by genetic mutations due to expansion of CAG trinucleotide and poly Q tract, for instance, Huntington’s disease and spinocerebellar ataxias. Some neurodegenerative diseases are caused due to aggregation of misfolded proteins, for instance Alzheimer’s disease, Huntington disease, and Parkinson’s disease. One of the common factors for cell death in neurodegeneration is intrinsic mitochondrial apoptotic pathway, for instance Amyotrophic lateral sclerosis. Alzheimer’s disease is caused due to aggregation of misfolded protein. Parkinson’s disease affects the central nervous system by abnormal accumulation of protein alpha-synuclein bound to ubiquitin in the damaged cells. Huntington’s disease is a genetic disorder that causes breakdown of nerve cells in the brain.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1860
Market Dynamics- Drivers
Availability of robust pipeline of drugs indicated for neurodegenerative disorders is expected to drive growth of the global neurodegenerative disease treatment market during the forecast period. For instance, in 2017, FlorbetapirF 18 sponsored by Avid Radiopharmaceuticals, a pharmaceutical company focused on improving clinical development of drugs completed phase 2 clinical trials. This drug is used as biomarkers for neurodegenerative diseases such as Alzheimer’s disease. F 18 T807 sponsored by Washington school of medicine is in phase 2 clinical trials since 2015. This drug is used to treat Amyotrophic Lateral Sclerosis (ALS).
Moreover, key players in the market are involved in mergers and acquisition, which in turn, is expected to drive the market growth in the near future. For instance, in June 2018, Alexion Pharmaceuticals Inc., a U.S.-based global biopharmaceutical company, merged with Complement Pharma, Netherlands-based Biotech Company, to develop preclinical C-6 complement inhibitor CP010 for neurodegenerative disorders such as Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS). C6 inhibition prevents the formation of Membrane attack complex (MAC), a complex of terminal complement proteins, which has potential to treat a variety of central nervous system disorders.
High prevalence of neurodegenerative and launch of new products is expected to propel the global neurodegenerative disease treatment market over the forecast period. For instance, in 2018, ArunA Biomedical launched exosome (Cell derived vesicles that are present in blood) biologic to treat Central Nervous System (CNS) and neurodegenerative diseases. Exosome biologics are used in treatment of CNS and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS).
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3sJsSi5
Increasing research for neurodegenerative diseases treatment is expected to boost growth of global neurodegenerative disease treatment market. For instance, E-Scape Bio, a biopharmaceutical company, would be investing more than US$ 63 million on research for treatment of Parkinson’s and Alzheimer’s disease from 2017 for development for new drug.
Market Dynamics- Restraints
Lack of reimbursement policies from the government and hospitals for the treatment of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS) is expected to restrain growth of the global neurodegenerative disease treatment market in the near future.
Among regions, North America is expected to hold dominant position in global neurodegenerative disease treatment market during the forecast period. This is owing to the strategic mergers and acquisitions among key players. For instance, in 2018, Abbvie Inc. a biopharmaceutical company merged with Voyager Therapeutics, a gene therapy developing company to develop gene therapies to treat Alzheimer’s disease. In 2014, Bristol Myers Squibb, an American pharmaceutical company acquired iPierian Inc. a drug discovery platform that develops therapies for neurodegenerative diseases. Bristol Myers Squibb acquired iPierian’s leading drug IPN007. IPN007 is a monoclonal antibody to treat progressive supranuclear palsy (a medical condition in which consists of deterioration of cells in various areas of brain that control thinking and body movement).
Furthermore, Europe neurodegenerative disease treatment market is expected to witness a significant growth, owing to increasing prevalence of neurodegenerative diseases in the region. According to a survey conducted by Parkinson Association of the Carolinas in 2016, more than 60000 new people in the U.S. are diagnosed with Parkinson’s disease annually. Therefore, increasing number of neurodegenerative disorders is in turn driving growth of the neurodegenerative disease treatment market in Europe.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/neurodegenerative-disease-treatment-market-1860
Key players operating in global neurodegenerative disease treatment market include Novartis AG, Pfizer Inc., Merck Serono, Biogen Inc., Teva Pharmaceutical Industries Ltd., UCB, C.H. Boehringer Sohn AG & Co. KG, Sanofi S.A., GlaxoSmithKline, and Neuro-Hitech Inc.
Global Neurodegenerative Disease Treatment Market Taxonomy:-
By Drugs Class:-
- NMDA Receptor
- Dopamine Inhibitors
- Cholinesterase Inhibitors
- SSRI Inhibitor
- Parkinson’s Disease
- Huntington Disease
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis
By Distribution Channel:-
- Online Pharmacies
- Retail Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire